A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/16/2006	WO2006121210A1 Agent for improving skin condition
11/16/2006	WO2006121209A1 Therapeutic agent for eczema and dermatitis
11/16/2006	WO2006121156A1 Medical composition for promotion of skin regeneration
11/16/2006	WO2006121151A1 Crystal of 1-methylcarbapenem compound
11/16/2006	WO2006121106A1 Method for producing indole derivative having piperidine ring
11/16/2006	WO2006121104A1 Crystal of indole derivative having piperidine ring and process for production thereof
11/16/2006	WO2006121097A1 Bicyclic heterocyclic derivative or salt thereof
11/16/2006	WO2006121095A1 Substituted acrylamide derivative and pharmaceutical composition comprising the same
11/16/2006	WO2006120974A1 Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage
11/16/2006	WO2006120915A1 Agent for improving circulatory disorder
11/16/2006	WO2006120851A1 Agent for imparting functions to textile products
11/16/2006	WO2006120705A2 Treatment and control of severe infections including cystic fibrosis
11/16/2006	WO2006120696A2 An improved pharmaceutical composition
11/16/2006	WO2006120682A2 Compositions and methods for treating hyperproliferative epidermal diseases
11/16/2006	WO2006120646A1 Topical use of teprenone
11/16/2006	WO2006120576A2 Immunogens for meningitidis-a vaccines
11/16/2006	WO2006120568A2 Pharmaceutical composition containing an anti parasitic agent and an active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone
11/16/2006	WO2006120567A2 Pharmaceutical composition comprising an anti-bacterial agent and an active ingredient selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120565A2 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol, carvacrol and alpha- and beta-ionones
11/16/2006	WO2006120564A1 Pharmaceutical composition comprising an antiviral agent, an antitumoral agent or an antiparasitic agent, and an active agent selected among carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120557A1 Anticancer combination therapy using sunitinib malate
11/16/2006	WO2006120552A2 ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
11/16/2006	WO2006120545A1 4' amino linked macrolides useful for the treatment of microbial infections
11/16/2006	WO2006120544A1 β-AMINO ACID DERIVATIVES
11/16/2006	WO2006120541A1 Ether linked macrolides useful for the treatment of microbial infections
11/16/2006	WO2006120520A1 Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
11/16/2006	WO2006120501A1 Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
11/16/2006	WO2006120500A1 Compositions and methods for inhibiting gastric acid secretion
11/16/2006	WO2006120496A1 Pharmaceutical combination comprising an antifungal agent and an active substance selected from carveol, eugenol, thymol, borneol and carvacrol
11/16/2006	WO2006120495A1 Pharmaceutical composition comprising an antiviral agent, an antitumour agent or an antiparasitic agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120494A1 Pharmaceutical combination comprising an antibacterial agent and an active substance selected from carveol, thymol, eugenol, borneol and carvacrol
11/16/2006	WO2006120481A2 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones which modulate the function of the vanilloid-1 receptor (vr1)
11/16/2006	WO2006120472A2 Novel beta-steroid compounds
11/16/2006	WO2006120465A2 Therapeutic sclerosing foam made preferably xenon
11/16/2006	WO2006120456A1 Pharmaceutical formulations of hdac inhibitors
11/16/2006	WO2006120448A1 Sublingual composition of ifenprodil
11/16/2006	WO2006120412A1 Pharmaceutical formulation of apomorphine for buccal administration
11/16/2006	WO2006120360A2 Active composition for treatment or prevention of problems related to a disturbance of the biological clock
11/16/2006	WO2006120349A1 Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
11/16/2006	WO2006120348A1 Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
11/16/2006	WO2006120268A1 Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds
11/16/2006	WO2006120266A1 Novel antioxidants which are obtained from a natural and synthetic source and method of obtaining same
11/16/2006	WO2006120251A1 Pteridines useful as hcv inhibitors and methods for the preparation thereof
11/16/2006	WO2006120178A1 New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
11/16/2006	WO2006120125A1 Diacylglycerol acyltransferase inhibitors
11/16/2006	WO2006120120A1 Use of docosahexaenoic glycerides for the treatment of tumorous diseases
11/16/2006	WO2006120104A1 Inhibitors of prolyl endopeptidase
11/16/2006	WO2006120010A2 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds
11/16/2006	WO2006120009A1 Production of glucosamine from plant species
11/16/2006	WO2006119975A1 Thienopyrroles as antiviral agents
11/16/2006	WO2006119958A2 Use of flibanserin in the treatment of chronic pain
11/16/2006	WO2006119884A2 Method for the treatment of drug abuse with flibanserin
11/16/2006	WO2006119844A2 Controlled release oral drug delivery system
11/16/2006	WO2006119803A1 USE OF 24-nor-UDCA
11/16/2006	WO2006119736A2 Pdz-domain modulators
11/16/2006	WO2006119697A1 Xylitol granules capable of directly being pressed into tablets and preparation process thereof
11/16/2006	WO2006119694A1 Quinolinone carboxylic acid derivatives, the preparation and the use thereof
11/16/2006	WO2006119692A1 A medicament for the treatment of hypertension
11/16/2006	WO2006119676A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119675A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119674A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119673A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
11/16/2006	WO2006119647A1 Oligonucleotides and methods of use
11/16/2006	WO2006119646A1 Compounds and methods for the treatment or prevention of flavivirus infections
11/16/2006	WO2006119643A1 Anti-ocular angiogenesis molecules and their uses
11/16/2006	WO2006119619A1 Oligonucleotides inhibiting cell proliferation
11/16/2006	WO2006119604A1 Method for preparing and using water-based steroid pheromone compositions
11/16/2006	WO2006119598A2 Transdermal device for the slow delivery of an omega-3-fatty acid, optionally in combination with a hmg coa reductase inhibitor
11/16/2006	WO2006119540A1 Preparation for treating psoriasis
11/16/2006	WO2006107957A3 Device and methods for treating paranasal sinus conditions
11/16/2006	WO2006105035A3 Muscarinic modulators
11/16/2006	WO2006102643A3 Stably transformed bone marrow-derived cells and uses thereof
11/16/2006	WO2006099479A3 Methods of treating cancer using ppar-gamma antagonists
11/16/2006	WO2006093401A9 Liquid non-flammable gas mixture and a container and package therefor
11/16/2006	WO2006093348A3 Method and composition for treating peripheral vascular diseases
11/16/2006	WO2006088541A3 Quinoline derivatives and uses thereof
11/16/2006	WO2006087652A3 Soap scent patch and treatment for muscle spasm and pain
11/16/2006	WO2006084913A3 Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide
11/16/2006	WO2006083924A8 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
11/16/2006	WO2006083424A3 Radiolabeled compounds and uses thereof
11/16/2006	WO2006081997A3 Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostate hyperplasia, prostate carcinoma, and spinobulbar muscular atrophy
11/16/2006	WO2006078833A3 Novel coumarin derivatives as ion channel openers
11/16/2006	WO2006078659A3 Stable prostaglandin-containing compositions
11/16/2006	WO2006074226A3 Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
11/16/2006	WO2006071691A3 Rnai inhibition of serum amyloid a for treatment of glaucoma
11/16/2006	WO2006065881A8 Use of ribose to alleviate rhabdomyolysis and the side effects of statin drugs
11/16/2006	WO2006061253A3 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
11/16/2006	WO2006060532A3 Formulations of substituted benzoxazoles
11/16/2006	WO2006055142A8 Taste-masked multiparticulate pharmaceutical compositions comprising a drug-containing core particle and a solvent-coacervated membrane
11/16/2006	WO2006052899A3 Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
11/16/2006	WO2006050489A3 Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
11/16/2006	WO2006044290A3 Biosynthesis of philoroglucinol and preparation of 1,3-dihydroxybenzene therefrom
11/16/2006	WO2006034395A3 Methods and compositions relating to mannuronic acid specific binding peptides
11/16/2006	WO2006034392A3 Therapeutic quinones
11/16/2006	WO2006034361A3 Dopaminergic mimetics
11/16/2006	WO2006015261A3 Nucleoside phosphonate conjugates as anti hiv agents
11/16/2006	WO2006014665A3 Arylpyrrolidine derivatives as nk-1/ssri antagonists
11/16/2006	WO2006002840A3 Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
11/16/2006	WO2006002077A3 Stable pharmaceutical formulations of benzimidazole compounds
11/16/2006	WO2006000589A8 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors

1 ... 4003 4004 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 ... 7860